• If you are wondering whether Cigna Group's current share price reflects its true worth, this breakdown of the company's value aims to give you a clear, structured view.
• Cigna Group recently closed at US$282.90, with returns of 2.6% over the last week, 4.8% over the last month, 1.4% year to date, and a 13.7% decline over the past year, compared with gains of 14.7% over three years and 18.5% over five years.
• Recent news coverage has focused on Cigna Group as a major health insurance and services business, including ongoing attention to its role in employer coverage, Medicare related offerings, and pharmacy benefit management. This backdrop helps frame how investors are weighing long term healthcare demand against policy and competitive pressures when assessing the stock.
• On Simply Wall St's 6 point valuation framework, Cigna Group currently scores a 6 out of 6. The next sections will walk through the different valuation approaches behind that score, then conclude with a broader way to think about what valuation means for you as an investor.

Approach 1: Cigna Group Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and discounting them back to a present value using a required rate of return.

For Cigna Group, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $7.27b. Analyst inputs and subsequent extrapolations project free cash flow of $10.17b in 2030, with annual projections between 2026 and 2035 discounted back to today.

Pulling these cash flows together, Simply Wall St arrives at an estimated intrinsic value of $896.95 per share. Compared with the recent share price of $282.90, this output suggests the stock is about 68.5% below the DCF estimate, which indicates a wide discount on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cigna Group is undervalued by 68.5%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Cigna Group Price vs Earnings

For a profitable company, the P/E ratio is a useful shorthand because it links what you pay per share to the earnings that each share generates. Investors generally accept that higher growth potential and lower perceived risk can support a higher “normal” or “fair” P/E, while slower growth and higher risk usually point to a lower P/E.

Cigna Group currently trades on a P/E of 11.90x. This sits below the Healthcare industry average P/E of 24.86x and also below the peer group average of 51.02x. On the surface, that gap suggests the market is assigning Cigna Group a lower earnings multiple than many Healthcare names.

Simply Wall St’s Fair Ratio, at 27.50x, is its proprietary estimate of what a suitable P/E could be for Cigna Group given factors such as earnings growth, profit margins, industry, market cap and company specific risks. This tends to be more tailored than a simple comparison with peers or the sector, which may include companies with very different growth profiles or risk levels. Comparing the Fair Ratio of 27.50x with the current 11.90x P/E indicates that Cigna Group’s shares may be trading at a discount on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Cigna Group Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about Cigna Group to the numbers by linking your view on its future revenue, earnings and margins to a forecast. This turns that into a fair value, which you can then compare with the current price to help you decide whether the stock suits your buy or sell plans. The fair value will automatically refresh when new news or earnings are released. For example, one investor on the Community page might build a more optimistic Cigna Narrative around specialty pharmacy growth, higher margins and a fair value near the upper analyst target of US$378. Another might emphasize regulatory and PBM risks and settle on a fair value closer to the lower target of US$290. Both are using the same accessible tool but with different assumptions.

Do you think there's more to the story for Cigna Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.